Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12345478 | 0.83 | MAOB (0.39) | MAOBMAOACYP1A2CYP2D6 | |
| SCHEMBL2796485 | 0.82 | IDO1 (0.47) | TAAR1IDO1AGXTALDH1A1MAOB | |
| SCHEMBL4310219 | 0.82 | IDO1 (0.55) | TAAR1IDO1AGXTMAOBMAOA | |
| SCHEMBL419919 | 0.81 | TAAR1 (0.57) | TAAR1IDO1AGXTALDH1A1MAOB | |
| SCHEMBL3185470 | 0.80 | TAAR1 (0.50) | TAAR1IDO1AGXTALDH1A1MAOB | |
| SCHEMBL27744248 | 0.80 | TAAR1 (0.55) | TAAR1IDO1AGXTMAOBMAOA | |
| SCHEMBL30581261 | 0.80 | TAAR1 (0.50) | TAAR1IDO1AGXTALDH1A1MAOB | |
| SCHEMBL6263676 | 0.80 | TAAR1 (0.50) | TAAR1IDO1AGXTALDH1A1MAOB | |
| SCHEMBL7008696 | 0.80 | TAAR1 (0.50) | TAAR1IDO1AGXTALDH1A1MAOB | |
| Propionaldehyde SCHEMBL27650408 | 0.79 | CYP1A2 (0.46) | TAAR1IDO1AGXTALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107118140-B | A kind of β-acyl group-allyl methyl sulfide derivative and preparation method thereof | 山西大学 | 2019-06-25 | — | — | CN | claimed |
| CN-107118140-A | A kind of β acyl groups pi-allyl methyl sulfide derivative and preparation method thereof | 山西大学 | 2017-09-01 | — | — | CN | claimed |
| WO-2006070244-A2 | A PROCESS FOR THE PREPARATION OF ZALEPLON | KHAMAR BAKULESH MAFATLAL (IN) | 2006-07-06 | — | — | WO | claimed |
| US-12545653-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| EP-4558501-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | SIONNA THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4398902-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF AMYLOID PEPTIDE INTERACTIONS WITH GLYCOSAMINOGLYCANS, METHODS OF TREATMENT, AND USE THEREOF | Gismo Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4396179-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118201919-A | Indole compounds and methods of use | 健赞公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-5599967-A | SKIN DISORDERS, VISION DISORDERS, ANTIINFLAMMATORY AGENTS | ALLERGAN | 1997-02-04 | — | — | US | disclosed |
| US-5591858-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | ALLERGAN | 1997-01-07 | — | — | US | disclosed |
| WO-1996033716-A1 | RARβ SELECTIVE RETINOID COMPOUNDS FOR INHIBITING GENE EXPRESSION PROMOTED BY AP1 PROTEIN AND THEIR USE IN THERAPY | ALLERGAN (US) | 1996-10-31 | — | — | WO | disclosed |
| US-5543534-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity | ALLERGAN | 1996-08-06 | — | — | US | disclosed |
| WO-1996020930-A1 | ACETYLENES DISUBSTITUTED WITH A 5 OR 8 SUBSTITUTED TETRAHYDRONAPHTHYL OR DIHYDRONAPHTHYL GROUP AND WITH AN ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996017851-A1 | ARTHROPODICIDAL AND FUNGICIDAL ORGANOSILANES AND ORGANOGERMANES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-06-13 | — | — | WO | disclosed |
| US-5514825-A | SYNTHETIC RETINOIDS | ALLERGAN, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| US-5489584-A | ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS; TREATING SKIN DISORDER, CARDIOVASCULAR DISORDER | ALLERGAN, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1994008976-A1 | FUNGICIDAL AND MITICIDAL AMINOPYRIMIDINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | TAAR1 1221/4885IDO1 3/4885AGXT 690/4885 |
| US-12545653-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARD, PPARG | TAAR1 877/4885IDO1 3642/4885AGXT 3230/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | TAAR1 762/4885IDO1 3872/4885AGXT 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.